VXRT News and Press, Vaxart Inc. From 05/14/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxart (NASDAQ: VXRT ) tried to produce a Covid-19 vaccine that could be taken orally as a pill, but it failed. As a result, VXRT stock is probably headed down 85% to its cash per share level, or about $1.00. Sour...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Is now the time to take a look at speculative Covid-19 play Vaxart (NASDAQ: VXRT ) stock? The clinical-stage biotech name has been at work on an oral coronavirus vaccine since before Covid-19 was declared a pandemic ...

Vaxart (VXRT), a clinical-stage biotech company, has made advances in developing a multivariant oral COVID-19 vaccine candidate. However, given that the vaccine candidate is still undergoing Phase I and Phase 2 clinical trials at a time when VXRT’s peers have long ago launched their va...

In the early days of the pandemic, Vaxart (NASDAQ: VXRT) mesmerized investors after beginning development of a tablet-based, room-temperature-stable coronavirus vaccine. The stock subsequently soared to a multiyear high of $24.90 per share in February, becoming a ten-bagger over a 1...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips An oral Covid-19 vaccine is, plain and simple, a great idea. Clinical-stage biotechnology company Vaxart  (NASDAQ: VXRT ) offers an alternative to inconvenient and uncomfortable injections. And so, you’d th...

Shares of vaccine expert Vaxart (NASDAQ: VXRT) have gone on a wild ride over the past 12 months as the company has released data for its coronavirus vaccine. In this video from Motley Fool Live , recorded on April 5 , Fool.com Contributors Brian Orelli and Keith Spei...

Vaxart (VXRT) has enrolled the first subject in a Phase 1b trial, VXA-NVV-104, evaluating safety and immunogenicity of oral norovirus vaccine in elderly subjects aged 55 – 80 years. The study drug will be an oral tablet administered on Days 1 and 29. “The norovirus program ...

Study will evaluate safety and immunogenicity of oral norovirus vaccine in elderly population Norovirus represents a significant unmet need in the elderly — there currently is no approved vaccine Safety and immunogenicity data to also inform oral COVID-19 vaccine program in...

Even with three COVID-19 vaccines already on the market in the U.S., the scramble to develop better vaccines is far from over. Ocugen (NASDAQ: OCGN) and Vaxart (NASDAQ: VXRT) stand out as two small companies hoping to achieve success. Vaxart's shares skyrocketed more tha...

James River Group Holdings (JRVR) -23% after stock offering and Q1 earnings release.Fastly (FSLY) -19% on Q1 earnings release.Regional Health Properties (RHE) -15%.Rocket Companies (RKT) -13% on Q1 earnings release.Etsy (ETSY) -11% on Q1 earnings releas...